Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib + Ipilimumab + Nivolumab in Metastatic Soft Tissue Sarcoma
NCT06968988Phase 1Suspended
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2026
- Primary completion
- Feb 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanzalintinib in soft tissue sarcoma (STS) (4 arms), sponsored by Washington University School of Medicine. Primary endpoint: Dose-Limiting Toxicities at 42 days. Started Jan 2026; status: suspended.
02
Drugs
zanzalintinib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06968988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06968988.